Bioxytran (BIXT) 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 01, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-35027
Entity Registrant Name	BIOXYTRAN, INC.
Entity Central Index Key	0001445815
Entity Tax Identification Number	26-2797630
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	75 2nd Avenue
Entity Address, Address Line Two	Ste 605
Entity Address, City or Town	Needham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02494
City Area Code	617
Local Phone Number	454-1199
Title of 12(b) Security	Common Stock, $0.001 par value per share
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		144,642,333

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)		Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash		$ 80,273	$ 295,401
Total current assets		80,273	295,401
Intangibles, net		108,770	75,535
Total assets		189,043	370,936
Current liabilities:
Accounts payable and accrued expenses		352,572	749,395
Convertible notes payable, net of premium and discount		1,900,000	2,165,000
Total current liabilities		2,332,958	3,663,482
Total liabilities		2,332,958	3,663,482
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 144,355,355 issued and outstanding as at September 30, 2023 and 123,252,235 as at December 31, 2022		144,355	123,252
Additional paid-in capital		12,821,885	8,392,430
Non-controlling interest		(659,063)	(590,628)
Accumulated deficit		(14,451,092)	(11,217,600)
Total stockholders’ deficit		(2,143,915)	(3,292,546)
Total liabilities and stockholders’ deficit		189,043	370,936
Related Party [Member]
Current liabilities:
Accounts payable, related party			709,727
Un-issued shares liability	[1]	45,000	38,400
Loan from related party		25,000
Nonrelated Party [Member]
Current liabilities:
Un-issued shares liability		$ 10,386	$ 960
[1]At September 30, 2023 the Company has not yet issued 233,163 45,000 0.193

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	144,355,355	123,252,235
Common stock, shares outstanding	144,355,355	123,252,235

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 316,129	$ 475,872	$ 604,771	$ 759,138
General and administrative	530,777	(563,604)	2,031,347	440,336
Compensation expense	138,558	73,507	157,268	142,630
Total net operating expenses	985,464	(14,225)	2,793,386	1,342,104
Net loss from operations	(985,464)	14,225	(2,793,386)	(1,342,104)
Other expenses:
Interest expense	(48,701)	(44,281)	(155,399)	(150,796)
Amortization of IP	(1,803)	(911)	(4,505)	(2,733)
Debt discount amortization and issuance of warrants		(172,182)	(348,637)	(304,941)
Total other expenses	(50,504)	(217,374)	(508,541)	(458,470)
Net loss before provision for income taxes	(1,035,968)	(203,149)	(3,301,927)	(1,800,574)
Provision for income taxes
NET LOSS	(1,035,968)	(203,149)	(3,301,927)	(1,800,574)
Net loss attributable to the non-controlling interest	34,777	79,507	68,435	142,314
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (1,001,191)	$ (123,642)	$ (3,233,492)	$ (1,658,260)
Loss per Common share, basic	$ (0.01)	$ 0	$ (0.02)	$ (0.01)
Loss per Common share, diluted	$ (0.01)	$ 0	$ (0.02)	$ (0.01)
Weighted average number of Common shares outstanding, basic	136,443,056	116,393,899	129,441,332	112,712,305
Weighted average number of Common shares outstanding, diluted	136,443,056	116,393,899	129,441,332	112,712,305

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Common Stock Including Additional Paid in Capital [Member]	Preferred Stock Including Additional Paid in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 110,841		$ 5,881,876		$ (8,753,668)	$ (397,256)	$ (3,158,207)
Balance, shares at Dec. 31, 2021	110,840,998
Issuance of Warrants			42,250				42,250
Net loss attributable to the non-controlling interest						(51,116)	(51,116)
Net loss					(912,270)		(912,270)
Balance at Mar. 31, 2022	$ 110,841		5,924,126		(9,665,938)	(448,372)	(4,079,343)
Balance, shares at Mar. 31, 2022	110,840,998
Balance at Dec. 31, 2021	$ 110,841		5,881,876		(8,753,668)	(397,256)	(3,158,207)
Balance, shares at Dec. 31, 2021	110,840,998
Net loss attributable to the non-controlling interest							(142,314)
Net loss							(1,658,260)
Balance at Sep. 30, 2022	$ 123,014		8,279,376		(10,411,929)	(539,570)	(2,549,109)
Balance, shares at Sep. 30, 2022	123,013,985
Balance at Dec. 31, 2021	$ 110,841		5,881,876		(8,753,668)	(397,256)	(3,158,207)
Balance, shares at Dec. 31, 2021	110,840,998
Balance at Dec. 31, 2022	$ 123,252		8,392,430		(11,217,600)	(590,628)	(3,292,546)
Balance, shares at Dec. 31, 2022	123,252,235
Balance at Mar. 31, 2022	$ 110,841		5,924,126		(9,665,938)	(448,372)	(4,079,343)
Balance, shares at Mar. 31, 2022	110,840,998
Net loss attributable to the non-controlling interest						(11,691)	(11,691)
Net loss					(622,349)		(622,349)
Cancellation of Stock Options – 2021 Plan			(47,267)				(47,267)
Balance at Jun. 30, 2022	$ 110,841		5,876,859		(10,288,287)	(460,063)	(4,760,650)
Balance, shares at Jun. 30, 2022	110,840,998
Issuance of Warrants			148,085				148,085
Net loss attributable to the non-controlling interest						(79,507)	(79,507)
Net loss					(123,642)		(123,642)
Correction for Stock Options – 2021 Plan			47,267				47,267
Forfeiture of Warrants			(6,763)				(6,763)
Shares issued to BoD & Mgmnt - 2021 Plan	$ 200		45,430				45,630
Shares issued to BoD & Mgmnt - 2021 Plan, shares	200,000
Shares issued to Consultants - 2021 Plan	$ 352		59,748				60,100
Shares issued to Consultants - 2021 Plan, shares	352,000
Sales of Shares	$ 1,400		598,600				600,000
Sales of Shares, shares	1,400,000
Conversion of warrants	$ 4,140		(4,140)
Conversion of warrants, shares	4,139,503
Conversion of Loan and accrued interest	$ 6,081		1,514,290				1,520,371
Conversion of Loan and accrued interest, shares	6,081,484
Balance at Sep. 30, 2022	$ 123,014		8,279,376		(10,411,929)	(539,570)	(2,549,109)
Balance, shares at Sep. 30, 2022	123,013,985
Balance at Dec. 31, 2022	$ 123,252		8,392,430		(11,217,600)	(590,628)	(3,292,546)
Balance, shares at Dec. 31, 2022	123,252,235
Net loss attributable to the non-controlling interest						(32,894)	(32,894)
Net loss					(785,083)		(785,083)
Stock transactions	$ 250		79,750				80,000
Stock transactions, shares	250,000
Stock subscription			(30,000)				(30,000)
Balance at Mar. 31, 2023	$ 123,502		8,442,180		(12,002,683)	(623,522)	(4,060,523)
Balance, shares at Mar. 31, 2023	123,502,235
Balance at Dec. 31, 2022	$ 123,252		8,392,430		(11,217,600)	(590,628)	(3,292,546)
Balance, shares at Dec. 31, 2022	123,252,235
Net loss attributable to the non-controlling interest							(68,435)
Net loss							(3,233,492)
Balance at Sep. 30, 2023	$ 144,355		12,821,885		(14,451,092)	(659,063)	(2,143,915)
Balance, shares at Sep. 30, 2023	144,355,355
Balance at Mar. 31, 2023	$ 123,502		8,442,180		(12,002,683)	(623,522)	(4,060,523)
Balance, shares at Mar. 31, 2023	123,502,235
Issuance of Warrants			348,637				348,637
Net loss attributable to the non-controlling interest						(764)	(764)
Net loss					(1,411,218)		(1,411,218)
Shares issued to BoD & Mgmnt - 2021 Plan	$ 110		50,090				50,200
Shares issued to BoD & Mgmnt - 2021 Plan, shares	110,000
Shares issued to Consultants - 2021 Plan	$ 4		1,786				1,790
Shares issued to Consultants - 2021 Plan, shares	4,000
Stock transactions	$ 192		64,808				65,000
Stock transactions, shares	192,411
Shares issued to BoD & Mgmnt for conversion of debt	$ 6,764		2,157,576				2,164,340
Shares issued to BoD & Mgmnt for conversion of debt, shares	6,763,562
Shares issued to Consultants for conversion of debt	$ 138		43,912				44,050
Shares issued to Consultants for conversion of debt, shares	137,656
Conversion of debt	$ 1,325		170,981				172,306
Conversion of debt, shares	1,325,430
Balance at Jun. 30, 2023	$ 132,035		11,279,970		(13,413,901)	(624,286)	(2,626,182)
Balance, shares at Jun. 30, 2023	132,035,294
Net loss attributable to the non-controlling interest						(34,777)	(34,777)
Net loss					(1,001,191)		(1,001,191)
Shares issued to BoD & Mgmnt - 2021 Plan	$ 120		17,820				17,940
Shares issued to BoD & Mgmnt - 2021 Plan, shares	120,000
Shares issued to Consultants - 2021 Plan	$ 477		70,835				71,312
Shares issued to Consultants - 2021 Plan, shares	477,000
Stock transactions	$ 3,188		387,173				390,361
Stock transactions, shares	3,188,459
Shares issued to BoD & Mgmnt for conversion of debt	$ 5,825		780,515				786,340
Shares issued to BoD & Mgmnt for conversion of debt, shares	5,824,741
Shares issued to Consultants for conversion of debt	$ 1,600		142,400				144,000
Shares issued to Consultants for conversion of debt, shares	1,600,000
Conversion of debt	$ 1,110		143,172				144,282
Conversion of debt, shares	1,109,861
Balance at Sep. 30, 2023	$ 144,355		$ 12,821,885		$ (14,451,092)	$ (659,063)	$ (2,143,915)
Balance, shares at Sep. 30, 2023	144,355,355

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,035,968)	$ (203,149)	$ (3,301,927)	$ (1,800,574)
Adjustments to reconcile net loss to net cash used in operating activities:
Debt discount amortization, incl. issuance of warrants			348,637	304,941
Amortization of IP	1,803	911	4,505	2,733
Stock-based compensation	138,558	73,507	157,268	142,630
Interest paid with note conversion			51,588	53,371
Changes in operating assets and liabilities:
Accounts payable and accrued expenses			(208,773)	(282,805)
Accounts payable, related party			2,265,953	(69,273)
Net cash used in operating activities			(682,749)	(1,648,977)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in intangibles			(37,740)	(30,151)
Net cash used in investing activities			(37,740)	(30,151)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from subsidiary stock transactions				600,000
Proceeds from stock sales			505,361
Proceeds from issuance of convertible notes payable				1,380,960
Net cash provided by financing activities			505,361	1,980,960
Net increase in cash			(215,128)	301,832
Cash, beginning of period			295,401	72,358	$ 72,358
Cash, end of period	$ 80,273	$ 374,190	80,273	374,190	$ 295,401
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid			52,425	69,900
Income taxes paid
NON-CASH INVESTING & FINANCING ACTIVITIES
Issuance of warrants			348,637	190,335
Forfeiture of warrants				(6,763)
Debt discount on convertible note				121,369
Common shares issued for the conversion of notes payable (principal and accrued interest)			316,588	1,520,371
Common shares issued for the exercise of warrants				$ 68,910

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (1,001,191)	$ (1,411,218)	$ (785,083)	$ (123,642)	$ (622,349)	$ (912,270)	$ (3,233,492)	$ (1,658,260)

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2023
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement	None of the Company’s directors or officers (as defined in Section 16 of the Exchange Act) adopted terminated
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BACKGROUND AND ORGANIZATION

BACKGROUND AND ORGANIZATION	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the “Company”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. Our Subsidiary, Pharmalectin, Inc. (the “Subsidiary”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to Covid-19. Our Foreign Subsidiary, Pharmalectin (BVI), Inc. (the “Foreign Subsidiary”) is the owner and custodian of the Company’s Copyrights, Trade Marks and Patents. Our subsidiary, Pharmalectin India Pvt Ltd. (“Pharmalectin India”) is managing the Company’s local clinical research and trials, and holds the local rights to commercialization. Organization Bioxytran, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 0.0001 5,000,000 0.0001 300,000,000 0.001 50,000,000 0.001 Pharmalectin was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 0.0001 5,000,000 0.0001 19,650,000 15,000,000 4,650,000 4,500,000 Pharmalectin BVI was organized on March 17, 2021 as a British Virgin Islands (BVI) Business Corporation with a BVI corporate taxing structure with 50,000 1.00 50,000 Pharmalectin India Pvt Ltd. (“Pharmalectin India”) was organized on August 30, 2022 as an Indian Business Corporation with its principal place of business in Hyderabad, Telangana, India, with 50,000 0.12 10 . 41,020 41,000 99.95% Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements. While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of the management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company’s December 31, 2022 audited financial statements and notes. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation, its majority owned subsidiary, Pharmalectin, Inc. of Delaware, as well as its wholly owned subsidiaries, Pharmalectin (BVI), Inc of British Virgin Islands and Pharmalectin India Pvt Ltd. (collectively, the “Company”). All intercompany accounts have been eliminated upon consolidation.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity date of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per Common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the “treasury stock” and/or “if converted” methods as applicable. At September 30, 2023, we would, based on the market price of $ 0.17 16,045,900 2,422,144 380,000 1,900,000 185,967 All of our currently outstanding notes have an interest rate of 6% Stock Based Compensation The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the nine months ended September 30, 2023 the Company incurred $ 604,771 759,138 Intangibles – Goodwill and Other Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company’s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent. Accrued Expenses As part of the process of preparing our condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S. Warrants The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed interim financial statements.

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	NOTE 3 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As at September 30, 2023, the Company had cash of $ 80,273 2,252,685 14,451,092 During the nine months ended September 30, 2023, the Company raised a net of $ 505,361 1,380,960 600,000 The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4 - RELATED PARTY TRANSACTIONS The Company hold License Agreements (the “License/s” or “Agreement/s”) for a medical device (license obtained in 2019) and a compound (license obtained in 2021), with two affiliated companies where in the officers of the Company hold a majority interest. The products were developed prior to the establishment of Bioxytran. The yearly maintenance fee for each license amount to $ 5,000 5,000 25,720 In the three months leading up to the financial close, the affiliate has advanced $ 25,000

INTANGIBLES

INTANGIBLES	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 5 - INTANGIBLES Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No Amortization of capitalized patent costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at the award date, which varies depending on the pendency period of the application, generally approximating twenty years. SCHEDULE OF INTANGIBLES Estimated Life (years) September 30, 2023 December 31, 2022 Capitalized patent costs 20 $ 116,919 $ 79,179 Accumulated amortization (8,149 ) (3,644 ) Intangible assets, net $ 108,770 $ 75,535

ACCOUNTS PAYABLES AND ACCRUED E

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 6 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On September 30, 2023, there was $ 25,000 45,000 709,727 38,400 The following table represents the major components of accounts payables and accrued expenses and other current liabilities at September 30, 2023 and at December 31, 2022: SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, 2023 December 31, 2022 Accounts payable related party (1) $ — $ 709,727 Professional fees 162,000 393,085 Interest 185,967 134,581 Payroll taxes — 40,182 Pension/401K — 180,557 Other 4,605 990 Un-issued share liability, related party (2) 45,000 38,400 Un-issued share liability, consultant 10,386 960 Un-issued share liability 10,386 960 Loan from related party 25,000 — Convertible note payable 1,900,000 2,165,000 Total $ 2,332,958 $ 3,663,482 (1) At September 30, 2023 there were no 286,900 269,400 153,427 (2) At September 30, 2023 the Company has not yet issued 233,163 45,000 0.193

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 7 – CONVERTIBLE NOTES PAYABLE Private Placement, 2021 Notes Around April 29, 2021, we entered into four (4) Securities Purchase Agreements (the “2021 SPA’s”), under which we agreed to sell convertible promissory notes (the “2021 Notes”), in an aggregate principal amount of $ 1,165,000 6 1,000,000 At any time after the issue date of the 2021 Notes, the Holders of the 2021 Notes, (the “2021 Holders”), have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the 2021 Notes into shares of our Common Stock at the Conversion Price. The “Conversion Price” will be the lesser of (i) $0.13 per share or (ii) 85% of the closing price of Any Qualified Financing, which consists of any fundraising whereby the Company receives gross proceeds of not less than $500,000 The variable conversion rate component requires that the 2021 Notes to be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the 2021 Notes. No such recording of a premium was required as the discounted “if-converted” rate of $ 0.13 The 2021 Holders are limited to holding a total of 4.99 The maturity on one note was negotiated to August 31, 2023 April 30, 2024 10 2,435,291 316,588 SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL Name Principal Converted Accrued interest converted No. of shares issued Private Placement, 2021 Notes issued to Officers (1) $ 265,000 $ 51,588 2,435,291 (1) Net cash received for these notes were $ 1,380,960 86,040 Convertible notes payable and interest payable consist of the following at September 30, 2023, and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2023 December 31, 2022 Principal balance (1) (2) $ 1,900,000 $ 2,165,000 Interest Payable 185,967 134,581 Outstanding, net of debt discount and premium $ 2,085,967 $ 2,299,581 (1) Net cash received for these notes were $ 1,045,150 119,850 265,000 (2) $ 2 1 There can be no assurance that there will be any funds available to pay of the 2021 Notes. If we fail to obtain such additional financing on a timely basis, the 2021 Holders may convert the 2021 Notes and sell the underlying shares, which may result in significant dilution to shareholders due to the conversion discount, as well as a significant decrease in our stock price. Private Placement, 2022 Notes converted into Common Stock In January, 2022, we entered into thirty-four (34) Securities Purchase Agreements (the “2022 SPA’s”), with accredited investors, under which we agreed to sell the Notes, in an aggregate principal amount of $ 1,467,000 6 At any time after the issue date of the 2022 Notes the 2022 Holders have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Notes into shares of our Common Stock at the Conversion Price. The “Conversion Price” is set to $ 0.25 The 2022 Holders are limited to holding a total of 4.99 The notes principal and accrued interest were fully converted into 6,081,484 Name Principal Converted Accrued interest converted No. of shares issued Private Placement, 2022 Notes (1) $ 1,467,000 $ 53,371 6,081,484 $ 1,467,000 $ 53,371 6,081,484 (1) Net cash received for these notes were $ 1,380,960 86,040

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY The Company is authorized to issue 300,000,000 50,000,000 Preferred stock As of September 30, 2023 and at December 31, 2022, no Common Stock On August 15, 2022 1,400,000 600,000 0.43 On August 31, 2022, 6,081,484 1,467,000 53,371 0.25 On September 8, 2022, 4,139,503 For the nine months ending September 30, 2022, 552,000 105,730 On January 4, 2023 the Company issued 93,750 30,000 0.32 On February 10, 2023 the Company issued 156,250 50,000 0.32 On April 14, 2023 the Company issued 137,656 44,050 0.32 On April 14, 2023 the Company issued 6,763,562 2,164,340 0.32 On April 18, 2023 the Company issued 78,125 25,000 0.32 On May 15, 2023 the Company issued 114,286 40,000 0.32 On May 17, 2023 the Company issued 522,138 67,878 0.13 On June 26, 2023 the Company issued 803,292 in a conversion of a note for a value of 104,428 in principal and interest 0.13 On July 26, 2023 the Company issued 500,000 against $ 100,000 0.20 On August 21, 2023, 1,612,903 145,161 0.09 On August 21, 2023, 1,600,000 145,000 0.09 On August 25, 2023, 505,186 68,200 0.135 On August 30, 2023 the Company issued 1,109,861 144,282 0.13 On September 14, 2023, 5,824,741 786,340 0.135 On September 19, 2023, the Company issued 200,000 against 27,000 0.135 On September 19, 2023, the Company issued 370,370 against 50,000 0.135 For the nine months ended September 30, 2023, a net of 711,000 141,796 0.20 As at September 30, 2023, the Company has 144,355,355 123,252,235 Common Stock Warrants For the nine months ended September 30, 2023 the Company issued 800,000 5 0.20 0.436 348,637 264,060 5 0.25 0.16 42,250 The fair value of stock warrants granted for the 9 months ended September 30, 2023 was calculated with the following assumptions: SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS September 30, 2023 September 30, 2022 Risk-free interest rate 3.97 % 1.53 % Expected dividend yield 0 % 0 % Volatility factor (monthly) 147.58 % 169.27 % Expected life of warrant 5 5 The following table summarizes the Company’s common stock warrant activity for the 9 months ended September 30, 2023 and 2022: SCHEDULE OF WARRANT ACTIVITY Number of Warrants* Weighted Average Exercise Price Weighted- Average Remaining Expected Term Outstanding as at January 1, 2022 272,000 $ 2.00 2.9 Granted 264,030 0.26 5.0 Exercised — — — Forfeited/Canceled — — — Outstanding as at September 30, 2022 536,030 1.14 3.5 Outstanding as at January 1, 2023 542,030 $ 0.42 4.1 Granted 800,000 0.20 5.0 Exercised — — — Forfeited/Canceled — — — Outstanding as at September 30, 2023 1,342,030 $ 0.29 4.1 * The warrant agreements issued in 2019 for a total of 50,000 1,130,114 0.09 873,704 The following table summarizes information about stock warrants that are vested or expected to vest at September 30, 2023: SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding Exercisable Warrants Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value 800,000 $ 0.20 4.6 $ — 800,000 $ 0.20 4.6 $ — 492,030 0.26 3.5 — 492,030 0.26 3.5 — 50,000 2.00 1.1 — 50,000 2.00 1.1 — 1,342,030 $ 0.29 4.1 $ — 1,342,030 $ 0.29 4.1 $ — The following table sets forth the status of the Company’s non-vested warrants as at September 30, 2023 and 2022: SCHEDULE OF NON-VESTED WARRANTS Number of Warrants Weighted-Average Grant-Date Fair Value Non-vested as at January 1, 2022 — — Granted 264,030 0.25 Forfeited — — Vested — — Non-vested as at September 30, 2022 — $ — Non-vested as at January 1, 2023 — $ — Granted 800,000 0.20 Forfeited — — Vested — — Non-vested as at September 30, 2023 — $ — Sales of Shares in Subsidiary For the nine months ended September 30, 2023 there were no 1,800,000 600,000

STOCK OPTION PLAN AND STOCK-BAS

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	NOTE 9 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION On January 19, 2021, the Board of Directors adopted the “2021 Stock Plan” (the “2021 Plan”) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights in an amount up to 15 90,000 5,001,709 Shares Awarded and Issued under the 2021 Plan: On January 10, 2022, the Company granted 40,000 6,400 0.16 On February 18, 2022, the Company granted 100,000 16,000 0.16 On April 1, 2022, the Company granted 10,000 1,730 0.173 On April 1, 2022, the Company granted 70,000 12,110 0.173 On April 11, 2022, the Company granted 250,000 43,250 0.173 On August 1, 2022, the Company issued 82,000 26,240 0.32 On April 19, 2023, the Company issued 110,000 0.46 50,200 On April 19, 2023, the Company granted 4,000 0.45 1,790 On August 4, 2023, the Company issued 120,000 0.15 17,940 On August 4, 2023, the Company granted 477,000 0.15 71,312 SCHEDULE OF FAIR MARKET VALUE Number of Shares Fair Value per Share Weighted Average Market Value per Share Shares Issued as of January 1, 2022 3,656,709 $ 0.001 $ 0.00 Shares Issued 552,000 0.16 0.32 0.22 Shares Issued as of September 30, 2022 4,208,709 $ 0.001 0.32 $ 0.00 Shares Issued as of January 1, 2023 4,290,709 $ 0.001 0.41 $ 0.00 Shares Issued 711,000 0.15 0.48 0.20 Shares Issued as of September 30, 2023 5,001,709 $ 0.001 0.48 $ 0.01 For the nine months ended September 30, 2023, the Company recorded stock-based compensation expense of $ 157,268 711,000 552,000 142,630 Stock options granted and vested 2021 Plan: There were no 144,000 96,000 The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023, and 2022: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Options Exercise Price per Share Weighted Average Exercise Price per Share Outstanding as of January 1, 2022 668,000 $ 0.001 1.21 $ 0.55 Granted — — — Exercised — — — Options forfeited/cancelled (96,000 ) 1.09 1.21 0.92 Outstanding as of September 30, 2022 572,000 $ 0.001 1.21 $ 0.45 Outstanding as of January 1, 2023 524,000 $ 0.001 0.95 $ 0.44 Granted — — — Exercised — — — Options forfeited/cancelled (144,000 ) 0.001 0.32 0.11 Outstanding as of September 30, 2023 380,000 $ 0.001 0.95 $ 0.48 The following table summarizes information about stock options that are vested or expected to vest at September 30, 2023: SCHEDULE OF STOCK OPTION VESTED Options Outstanding Exercisable Options Exercise Price Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value $ 0.001 45,000 $ 0.001 0.83 $ 7,650 45,000 $ 0.001 0.83 $ 7,650 0.18 45,000 0.18 0.08 — 45,000 0.18 0.08 — 0.19 45,000 0.19 0.58 — 45,000 0.19 0.58 — 0.20 45,000 0.20 0.34 — 45,000 0.20 0.34 — 0.95 200,000 0.95 0.51 — 200,000 0.95 0.51 — $ 0.001 0.95 380,000 $ 0.48 0.57 $ 7,650 380,000 $ 0.48 0.57 $ 7,650 The weighted-average remaining estimated life for options exercisable at September 30, 2023 is 0.48 The aggregate intrinsic value for fully vested, exercisable options was $ 7,650 0 no As at September 30, 2023 the Company has 20,875,870

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
NON-CONTROLLING INTEREST	NOTE 10 – NON-CONTROLLING INTEREST SCHEDULE OF NON CONTROLLING INTEREST September 30, 2023 December 31, 2022 Net loss Subsidiary $ (289,191 ) $ (817,151 ) Net loss attributable to the non-controlling interest 68,435 193,372 Net loss affecting Bioxytran (220,756 ) (623,780 ) Accumulated losses (3,861,549 ) (3,594,287 ) Accumulated losses attributable to the non-controlling interest 820,013 751,578 Accumulated losses Bioxytran (3,041,536 ) (2,842,709 ) Net equity non-controlling interest $ (659,063 ) $ (590,628 ) As at September 30, 2023 and at December 31, 2022 there are 19,650,000 15,000,000 4,650,000 4,500,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES Employment contracts Our Executive Officers have entered into employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The most substantial provisions include; ● Compensation of three (3) times the employee’s annual salary upon the Termination Date and any target bonus earned, or if termination occurs within 12 months of a change in control, then the terminated employee shall receive two (2) times the employee’s annual salary and any target bonus earned. ● Continued coverage under any health, medical, dental or vision program or policy, in which they were eligible to participate at the time of employment termination, for 12 months. ● Provide outplacement services through one or more outside firms of the employee’s choosing up to an aggregate of $ 50,000 There are no other arrangements or plans in which we provide pension, retirement or similar benefits for any of Executive Officers or Directors. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS The Company has evaluated events from September 30, 2023 through the date the financial statements were issued. and did not, other than what is disclosed in the below, identify any further subsequent events requiring disclosure. Shares awarded under the 2021 Stock Plan: On October 27, 2023, the Company granted 53,815 10,386 0.193 On October 27, 2023, the Company granted 233,163 45,000 0.193 Stock options forfeited under the 2021 Stock Plan: On October 30, 2023, 45,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Cash	Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity date of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Net Loss per Common Share, basic and diluted	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per Common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the “treasury stock” and/or “if converted” methods as applicable. At September 30, 2023, we would, based on the market price of $ 0.17 16,045,900 2,422,144 380,000 1,900,000 185,967 All of our currently outstanding notes have an interest rate of 6%
Stock Based Compensation	Stock Based Compensation The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash.
Research and Development	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the nine months ended September 30, 2023 the Company incurred $ 604,771 759,138
Intangibles – Goodwill and Other	Intangibles – Goodwill and Other Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company’s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent.
Accrued Expenses	Accrued Expenses As part of the process of preparing our condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.
Warrants	Warrants The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.
Fair Value	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed interim financial statements.

INTANGIBLES (Tables)

INTANGIBLES (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLES	SCHEDULE OF INTANGIBLES Estimated Life (years) September 30, 2023 December 31, 2022 Capitalized patent costs 20 $ 116,919 $ 79,179 Accumulated amortization (8,149 ) (3,644 ) Intangible assets, net $ 108,770 $ 75,535

ACCOUNTS PAYABLES AND ACCRUED_2

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	The following table represents the major components of accounts payables and accrued expenses and other current liabilities at September 30, 2023 and at December 31, 2022: SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, 2023 December 31, 2022 Accounts payable related party (1) $ — $ 709,727 Professional fees 162,000 393,085 Interest 185,967 134,581 Payroll taxes — 40,182 Pension/401K — 180,557 Other 4,605 990 Un-issued share liability, related party (2) 45,000 38,400 Un-issued share liability, consultant 10,386 960 Un-issued share liability 10,386 960 Loan from related party 25,000 — Convertible note payable 1,900,000 2,165,000 Total $ 2,332,958 $ 3,663,482 (1) At September 30, 2023 there were no 286,900 269,400 153,427 (2) At September 30, 2023 the Company has not yet issued 233,163 45,000 0.193

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL	SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL Name Principal Converted Accrued interest converted No. of shares issued Private Placement, 2021 Notes issued to Officers (1) $ 265,000 $ 51,588 2,435,291 (1) Net cash received for these notes were $ 1,380,960 86,040 Name Principal Converted Accrued interest converted No. of shares issued Private Placement, 2022 Notes (1) $ 1,467,000 $ 53,371 6,081,484 $ 1,467,000 $ 53,371 6,081,484 (1) Net cash received for these notes were $ 1,380,960 86,040
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	Convertible notes payable and interest payable consist of the following at September 30, 2023, and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2023 December 31, 2022 Principal balance (1) (2) $ 1,900,000 $ 2,165,000 Interest Payable 185,967 134,581 Outstanding, net of debt discount and premium $ 2,085,967 $ 2,299,581 (1) Net cash received for these notes were $ 1,045,150 119,850 265,000 (2) $ 2 1

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS	The fair value of stock warrants granted for the 9 months ended September 30, 2023 was calculated with the following assumptions: SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS September 30, 2023 September 30, 2022 Risk-free interest rate 3.97 % 1.53 % Expected dividend yield 0 % 0 % Volatility factor (monthly) 147.58 % 169.27 % Expected life of warrant 5 5
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes the Company’s common stock warrant activity for the 9 months ended September 30, 2023 and 2022: SCHEDULE OF WARRANT ACTIVITY Number of Warrants* Weighted Average Exercise Price Weighted- Average Remaining Expected Term Outstanding as at January 1, 2022 272,000 $ 2.00 2.9 Granted 264,030 0.26 5.0 Exercised — — — Forfeited/Canceled — — — Outstanding as at September 30, 2022 536,030 1.14 3.5 Outstanding as at January 1, 2023 542,030 $ 0.42 4.1 Granted 800,000 0.20 5.0 Exercised — — — Forfeited/Canceled — — — Outstanding as at September 30, 2023 1,342,030 $ 0.29 4.1 * The warrant agreements issued in 2019 for a total of 50,000 1,130,114 0.09 873,704
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS	The following table summarizes information about stock warrants that are vested or expected to vest at September 30, 2023: SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding Exercisable Warrants Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value 800,000 $ 0.20 4.6 $ — 800,000 $ 0.20 4.6 $ — 492,030 0.26 3.5 — 492,030 0.26 3.5 — 50,000 2.00 1.1 — 50,000 2.00 1.1 — 1,342,030 $ 0.29 4.1 $ — 1,342,030 $ 0.29 4.1 $ —
SCHEDULE OF NON-VESTED WARRANTS	The following table sets forth the status of the Company’s non-vested warrants as at September 30, 2023 and 2022: SCHEDULE OF NON-VESTED WARRANTS Number of Warrants Weighted-Average Grant-Date Fair Value Non-vested as at January 1, 2022 — — Granted 264,030 0.25 Forfeited — — Vested — — Non-vested as at September 30, 2022 — $ — Non-vested as at January 1, 2023 — $ — Granted 800,000 0.20 Forfeited — — Vested — — Non-vested as at September 30, 2023 — $ —

STOCK OPTION PLAN AND STOCK-B_2

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF FAIR MARKET VALUE	SCHEDULE OF FAIR MARKET VALUE Number of Shares Fair Value per Share Weighted Average Market Value per Share Shares Issued as of January 1, 2022 3,656,709 $ 0.001 $ 0.00 Shares Issued 552,000 0.16 0.32 0.22 Shares Issued as of September 30, 2022 4,208,709 $ 0.001 0.32 $ 0.00 Shares Issued as of January 1, 2023 4,290,709 $ 0.001 0.41 $ 0.00 Shares Issued 711,000 0.15 0.48 0.20 Shares Issued as of September 30, 2023 5,001,709 $ 0.001 0.48 $ 0.01
SCHEDULE OF STOCK OPTIONS ACTIVITY	The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023, and 2022: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Options Exercise Price per Share Weighted Average Exercise Price per Share Outstanding as of January 1, 2022 668,000 $ 0.001 1.21 $ 0.55 Granted — — — Exercised — — — Options forfeited/cancelled (96,000 ) 1.09 1.21 0.92 Outstanding as of September 30, 2022 572,000 $ 0.001 1.21 $ 0.45 Outstanding as of January 1, 2023 524,000 $ 0.001 0.95 $ 0.44 Granted — — — Exercised — — — Options forfeited/cancelled (144,000 ) 0.001 0.32 0.11 Outstanding as of September 30, 2023 380,000 $ 0.001 0.95 $ 0.48
SCHEDULE OF STOCK OPTION VESTED	The following table summarizes information about stock options that are vested or expected to vest at September 30, 2023: SCHEDULE OF STOCK OPTION VESTED Options Outstanding Exercisable Options Exercise Price Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value $ 0.001 45,000 $ 0.001 0.83 $ 7,650 45,000 $ 0.001 0.83 $ 7,650 0.18 45,000 0.18 0.08 — 45,000 0.18 0.08 — 0.19 45,000 0.19 0.58 — 45,000 0.19 0.58 — 0.20 45,000 0.20 0.34 — 45,000 0.20 0.34 — 0.95 200,000 0.95 0.51 — 200,000 0.95 0.51 — $ 0.001 0.95 380,000 $ 0.48 0.57 $ 7,650 380,000 $ 0.48 0.57 $ 7,650

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
SCHEDULE OF NON CONTROLLING INTEREST	SCHEDULE OF NON CONTROLLING INTEREST September 30, 2023 December 31, 2022 Net loss Subsidiary $ (289,191 ) $ (817,151 ) Net loss attributable to the non-controlling interest 68,435 193,372 Net loss affecting Bioxytran (220,756 ) (623,780 ) Accumulated losses (3,861,549 ) (3,594,287 ) Accumulated losses attributable to the non-controlling interest 820,013 751,578 Accumulated losses Bioxytran (3,041,536 ) (2,842,709 ) Net equity non-controlling interest $ (659,063 ) $ (590,628 )

BACKGROUND AND ORGANIZATION (De

BACKGROUND AND ORGANIZATION (Details Narrative)	Aug. 30, 2022 $ / shares shares	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Aug. 30, 2022 ₨ / shares shares	Mar. 17, 2021 $ / shares shares	Sep. 21, 2018 $ / shares shares	Oct. 05, 2017 $ / shares shares
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares authorized		300,000,000	300,000,000
Common stock, par value | $ / shares		$ 0.001	$ 0.001
Common stock, shares authorized		50,000,000	50,000,000
Preferred stock, par value | $ / shares		$ 0.001	$ 0.001
Common stock, shares issued		144,355,355	123,252,235
Common stock, shares outstanding		144,355,355	123,252,235
Pharmalectin (BVI), Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares authorized					50,000
Common stock, par value | $ / shares					$ 1
Common stock, shares outstanding		50,000
Pharmalectin India Pv tLtd [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares authorized	50,000			50,000
Common stock, par value | (per share)	$ 0.12			₨ 10
Common stock, shares outstanding	41,020			41,020
Common stock shares outstanding round off	41,000			41,000
Percentage of outstanding shares	99.95%
Parent Company [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares authorized						300,000,000	95,000,000
Common stock, par value | $ / shares						$ 0.001	$ 0.0001
Common stock, shares authorized						50,000,000	5,000,000
Preferred stock, par value | $ / shares						$ 0.001	$ 0.0001
Pharmalectin, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares authorized							95,000,000
Common stock, par value | $ / shares							$ 0.0001
Common stock, shares authorized							5,000,000
Preferred stock, par value | $ / shares							$ 0.0001
Common stock, shares issued		19,650,000	19,650,000
Common stock, shares outstanding		19,650,000	19,650,000
Pharmalectin, Inc. [Member] | Parent Company [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares outstanding		15,000,000	15,000,000
Pharmalectin, Inc. [Member] | Affiliate [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares outstanding		4,650,000
Options outstanding		4,500,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Aug. 21, 2023	Aug. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 19, 2023	Jul. 26, 2023	May 15, 2023	Apr. 18, 2023	Feb. 10, 2023
Short-Term Debt [Line Items]
Market price							$ 0.135	$ 0.20	$ 0.32	$ 0.32	$ 0.32
Common stock shares issued upon conversion of debt	1,612,903	6,081,484
Research and development expenses			$ 316,129	$ 475,872	$ 604,771	$ 759,138
Promissory Notes [Member]
Short-Term Debt [Line Items]
Market price			$ 0.17		$ 0.17
Common stock shares issued upon conversion of debt					16,045,900
Shares issued upon exercise of warrants					2,422,144
Shares issued upon exercise of outstanding options					380,000
Principal and unpaid interest			$ 1,900,000		$ 1,900,000
Increase for accrued, but unpaid interest on the debt instrument for the period.					$ 185,967
Debt Conversion, Description					All of our currently outstanding notes have an interest rate of 6% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising whereby the Company receives gross proceeds of not less than $500,000. The notes contain a conversion limitation which prevents the holder(s) of the notes from converting if doing so would result in the holder beneficially owning more than 4.99% of our issued an outstanding Common Stock.
Debt Interest rate					6%

GOING CONCERN AND MANAGEMENT__2

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 80,273		$ 295,401
Working capital	2,252,685
Accumulated deficit	14,451,092		$ 11,217,600
Proceeds from issuance of common stock	505,361	$ 600,000
Proceeds from issuance of convertible notes payable		$ 1,380,960

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Reimbursement of legal and administrative costs		$ 25,720
Payments for advance to affiliate	$ 25,000
Two Affiliated Companies [Member]
Related Party Transaction [Line Items]
Maintanence costs of licene agreements of two affiliates each	5,000
Affiliated Entity Two [Member]
Related Party Transaction [Line Items]
License fee	$ 5,000

SCHEDULE OF INTANGIBLES (Detail

SCHEDULE OF INTANGIBLES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Estimated Remaining Life (years)	20 years
Capitalized patent costs	$ 116,919	$ 79,179
Accumulated amortization	(8,149)	(3,644)
Intangible assets, net	$ 108,770	$ 75,535

INTANGIBLES (Details Narrative)

INTANGIBLES (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment charges of intangibles	$ 0	$ 0

SCHEDULE OF ACCOUNTS PAYABLES A

SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)		Sep. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Professional fees		$ 162,000	$ 393,085
Interest		185,967	134,581
Payroll taxes			40,182
Pension/401K			180,557
Other		4,605	990
Convertible note payable		1,900,000	2,165,000
Total current liabilities		2,332,958	3,663,482
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accounts payable related party	[1]		709,727
Un-issued share liability	[2]	45,000	38,400
Loan from related party		25,000
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Un-issued share liability		$ 10,386	$ 960
[1]At September 30, 2023 there were no 286,900 269,400 153,427 233,163 45,000 0.193

SCHEDULE OF ACCOUNTS PAYABLES_2

SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Accounts payable	$ 0
Gross number of share options (or share units) granted during the period.	233,163
Four Board Members [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of common stock awarded not issued	$ 45,000
Price per share	$ 0.193
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued salary		$ 286,900
Chief Financial Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued salary		269,400
Chief Communications Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued salary		$ 153,427

ACCOUNTS PAYABLES AND ACCRUED_3

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details Narrative) - Related Party [Member] - USD ($)		Sep. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Loan from related party		$ 25,000
Un-issued shares liability related party	[1]	45,000	38,400
Accounts payable to related parties	[2]		$ 709,727
[1]At September 30, 2023 the Company has not yet issued 233,163 45,000 0.193 no 286,900 269,400 153,427

SCHEDULE OF CONVERTIBLE CONVERS

SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL (Details) - USD ($)					9 Months Ended
		Aug. 25, 2023	Aug. 21, 2023	Aug. 31, 2022	Sep. 30, 2023
Short-Term Debt [Line Items]
Principal Converted			$ 145,161	$ 1,467,000
Accrued interest converted				$ 53,371
Shares issued			1,612,903	6,081,484
Private Placement [Member]
Short-Term Debt [Line Items]
Principal Converted		$ 68,200
Shares issued		505,186
Private Placement [Member] | 2021 Notes [Member] | Officer [Member]
Short-Term Debt [Line Items]
Principal Converted	[1]				$ 265,000
Accrued interest converted	[1]				$ 51,588
Shares issued	[1]				2,435,291
Private Placement [Member] | 2022 Notes [Member]
Short-Term Debt [Line Items]
Principal Converted	[2]			$ 1,467,000
Accrued interest converted	[2]			$ 53,371
Shares issued	[2]			6,081,484
[1]Net cash received for these notes were $ 1,380,960 86,040 1,380,960 86,040

SCHEDULE OF CONVERTIBLE CONVE_2

SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL (Details) (Parenthetical) - USD ($)		Sep. 30, 2023	Dec. 31, 2022	Aug. 31, 2022
Short-Term Debt [Line Items]
Face value	[1],[2]	$ 1,900,000	$ 2,165,000
Note Sold in Exchange for Cash [Member] | WallachBeth Capital, LLC [Member]
Short-Term Debt [Line Items]
Face value				$ 1,380,960
Debt discount				$ 86,040
[1]$ 2 1 1,045,150 119,850 265,000

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)		Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Principal balance	[1],[2]	$ 1,900,000	$ 2,165,000
Interest payable		185,967	134,581
Debt discount and premium		$ 2,085,967	$ 2,299,581
[1]$ 2 1 1,045,150 119,850 265,000

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) - USD ($)						9 Months Ended		12 Months Ended
	Aug. 30, 2023	Aug. 21, 2023	Jun. 26, 2023	May 17, 2023	Aug. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Short-Term Debt [Line Items]
Cash received							$ 1,380,960
Common stock shares issued upon conversion of debt		1,612,903			6,081,484
Principal accrued interest settled						2,000,000
Reissue of note for settlement						$ 1,000,000
Note Sold in Exchange for Cash [Member] | WallachBeth Capital, LLC [Member]
Short-Term Debt [Line Items]
Cash received								$ 1,045,150
Debt discount								$ 119,850
2021 Notes [Member] | WallachBeth Capital, LLC [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Common stock shares issued upon conversion of debt	265,000		265,000	265,000

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)								1 Months Ended
		Aug. 30, 2023	Aug. 21, 2023	Jun. 26, 2023	May 17, 2023	Aug. 31, 2022	Apr. 29, 2021	Jan. 31, 2022	Sep. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Aggregate principal amount	[1],[2]								$ 1,900,000	$ 2,165,000
Shares issued			1,612,903			6,081,484
Shares issued for conversion of debt, value			$ 145,161			$ 1,467,000
Debt conversion price			$ 0.09
Four Securities Purchase Agreements [Member] | Convertible Notes Payable [Member] | 2021 Notes [Member]
Short-Term Debt [Line Items]
Aggregate principal amount							$ 1,165,000
Interest rate							6%
Proceeds from notes payable							$ 1,000,000
Note conversion description							The “Conversion Price” will be the lesser of (i) $0.13 per share or (ii) 85% of the closing price of Any Qualified Financing, which consists of any fundraising whereby the Company receives gross proceeds of not less than $500,000
Shares price							$ 0.13
Issued and outstanding common stock, percentage							4.99%
Three Securities Purchase Agreements [Member] | Convertible Notes Payable [Member] | 2021 Notes [Member]
Short-Term Debt [Line Items]
Interest rate									10%
Two Securities Purchase Agreements [Member] | Convertible Notes Payable [Member] | 2021 Notes [Member]
Short-Term Debt [Line Items]
Shares issued					2,435,291
Shares issued for conversion of debt, value		$ 316,588		$ 316,588
Thirty Four Securities Purchase Agreement [Member] | Convertible Notes Payable [Member] | 2022 Notes [Member]
Short-Term Debt [Line Items]
Aggregate principal amount								$ 1,467,000
Interest rate								6%
Issued and outstanding common stock, percentage								4.99%
Debt conversion price								$ 0.25
[1]$ 2 1 1,045,150 119,850 265,000

SCHEDULE OF STOCK WARRANTS VALU

SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk-free interest rate	3.97%	1.53%
Expected dividend yield	0%	0%
Volatility factor (monthly)	147.58%	169.27%
Expected life of warrant	5 years	5 years

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Number of warrants oustanding, Beginning balance	[1]	542,030	272,000
Weighted average exercise price, Beginning balance		$ 0.42	$ 2
Weighted average remaining contractual term, Beginning balance		4 years 1 month 6 days	2 years 10 months 24 days
Number of warrants, Granted	[1]	800,000	264,030
Weighted average exercise price, Granted		$ 0.20	$ 0.26
Weighted average remaining contractual term, Granted		5 years	5 years
Number of warrants, Exercised	[1]
Weighted average exercise price, Exercised
Number of warrants, Forfeited and cancelled	[1]
Weighted average exercise price, Forfeited and cancelled
Number of warrants oustanding, Ending balance	[1]	1,342,030	536,030
Weighted average exercise price, Ending balance		$ 0.29	$ 1.14
Weighted average remaining contractual term, Ending balance		4 years 1 month 6 days	3 years 6 months
[1]The warrant agreements issued in 2019 for a total of 50,000 1,130,114 0.09 873,704

SCHEDULE OF WARRANT ACTIVITY _2

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - Warrant Agreements [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant issued		50,000
Warrant exercised, shares issued	1,130,114
Warrant exercise price	$ 0.09
Warrant cashless exercised, shares issued	873,704

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS (Details) - USD ($)		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Number of Warrants	[1]	1,342,030	536,030	542,030	272,000
Warrants Outstanding, Weighted Average Exercise Price Per Share		$ 0.29	$ 1.14	$ 0.42	$ 2
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)		4 years 1 month 6 days	2 years 10 months 24 days
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Number of Warrants		800,000
Warrants Outstanding, Weighted Average Exercise Price Per Share		$ 0.20
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)		4 years 7 months 6 days
Warrants Outstanding, Aggregate Intrinsic Value
Warrants Exercisable, Number of Warrants		800,000
Warrants Exercisable, Weighted Average Exercise Price Per Share		$ 0.20
Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)		4 years 7 months 6 days
Warrants Exercisable, Aggregate Intrinsic Value
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Number of Warrants		492,030
Warrants Outstanding, Weighted Average Exercise Price Per Share		$ 0.26
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)		3 years 6 months
Warrants Outstanding, Aggregate Intrinsic Value
Warrants Exercisable, Number of Warrants		492,030
Warrants Exercisable, Weighted Average Exercise Price Per Share		$ 0.26
Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)		3 years 6 months
Warrants Exercisable, Aggregate Intrinsic Value
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Number of Warrants		50,000
Warrants Outstanding, Weighted Average Exercise Price Per Share		$ 2
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)		1 year 1 month 6 days
Warrants Outstanding, Aggregate Intrinsic Value
Warrants Exercisable, Number of Warrants		50,000
Warrants Exercisable, Weighted Average Exercise Price Per Share		$ 2
Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)		1 year 1 month 6 days
Warrants Exercisable, Aggregate Intrinsic Value
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Number of Warrants		1,342,030
Warrants Outstanding, Weighted Average Exercise Price Per Share		$ 0.29
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)		4 years 1 month 6 days
Warrants Outstanding, Aggregate Intrinsic Value
Warrants Exercisable, Number of Warrants		1,342,030
Warrants Exercisable, Weighted Average Exercise Price Per Share		$ 0.29
Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)		4 years 1 month 6 days
Warrants Exercisable, Aggregate Intrinsic Value
[1]The warrant agreements issued in 2019 for a total of 50,000 1,130,114 0.09 873,704

SCHEDULE OF NON-VESTED WARRANTS

SCHEDULE OF NON-VESTED WARRANTS (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Number of Warrants Non-vested, Beginning
Weighted- Average Grant-Date Fair Value per share Non-vested, Beginning
Number of Warrants Non-vested, Granted	800,000	264,030
Weighted- Average Grant-Date Fair Value per share Non-vested, Granted	$ 0.20	$ 0.25
Number of Warrants Non-vested, Forfeited
Weighted- Average Grant-Date Fair Value per share Non-vested, Forfeited
Number of Warrants Non-vested, Vested
Weighted- Average Grant-Date Fair Value per share Non-vested, Vested
Number of Warrants Non-vested, Ending
Weighted- Average Grant-Date Fair Value per share Non-vested, Ending

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)																		3 Months Ended			9 Months Ended
	Sep. 19, 2023	Sep. 14, 2023	Aug. 30, 2023	Aug. 25, 2023	Aug. 21, 2023	Jul. 26, 2023	Jun. 26, 2023	May 17, 2023	May 15, 2023	Apr. 18, 2023	Apr. 14, 2023	Feb. 10, 2023	Jan. 04, 2023	Sep. 08, 2022	Aug. 31, 2022	Aug. 31, 2022	Aug. 15, 2022	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Oct. 05, 2017
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized																		300,000,000			300,000,000		300,000,000
Preferred stock, shares authorized																		50,000,000			50,000,000		50,000,000
Preferred Stock, Shares Issued
Value of shares sold																				$ 600,000
Shares issued for conversion of debt, shares					1,612,903										6,081,484
Shares issued for conversion of debt, value					$ 145,161										$ 1,467,000
Interest																		$ 185,967			$ 185,967		$ 134,581
Conversion price					$ 0.09
New issues, shares	200,000					500,000			114,286	78,125		156,250
Stock issued value	$ 27,000					$ 100,000			$ 40,000	$ 25,000		$ 50,000						$ 17,940	$ 50,200	$ 45,630
Share price	$ 0.135					$ 0.20			$ 0.32	$ 0.32		$ 0.32
Common stock, shares, issued																		144,355,355			144,355,355		123,252,235
Common stock, shares, outstanding																		144,355,355			144,355,355		123,252,235
Pharmalectin, Inc. [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized																								95,000,000
Preferred stock, shares authorized																								5,000,000
Sales of shares																						1,800,000
Value of shares sold																						$ 600,000
Common stock, shares, issued																		19,650,000			19,650,000		19,650,000
Common stock, shares, outstanding																		19,650,000			19,650,000		19,650,000
Common Stock One [Member]
Subsidiary, Sale of Stock [Line Items]
New issues, shares	370,370
Stock issued value	$ 50,000
Share price	$ 0.135
Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																		$ 0.436		$ 0.16	$ 0.436	$ 0.16
Number of warrants issued																		800,000		264,060	800,000	264,060
Warrant term																		5 years		5 years	5 years	5 years
Warrant exercise price																		$ 0.20		$ 0.25	$ 0.20	$ 0.25
Fair value of warrants issued																		$ 348,637		$ 42,250	$ 348,637	$ 42,250
Invoice Exchange [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for conversion of debt, shares		5,824,741			1,600,000
Shares issued for conversion of debt, value		$ 786,340			$ 145,000
Conversion price		$ 0.135			$ 0.09
Supplier Invoice [Member]
Subsidiary, Sale of Stock [Line Items]
New issues, shares											137,656
Stock issued value											$ 44,050
Share price											$ 0.32
Officers [Member]
Subsidiary, Sale of Stock [Line Items]
New issues, shares											6,763,562
Stock issued value											$ 2,164,340
Share price											$ 0.32
Subscription Arrangement [Member]
Subsidiary, Sale of Stock [Line Items]
New issues, shares													93,750
Stock issued value													$ 30,000
Share price													$ 0.32
2021 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued under plan																					711,000	552,000
Value of shares issued under plan																					$ 141,796	$ 105,730
Share price																		$ 0.20			$ 0.20
Four Outstanding Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued during period issue in exchange of cashless exercise														4,139,503
Convertible Notes [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for conversion of debt, shares			1,109,861				803,292	522,138							6,081,484
Shares issued for conversion of debt, value			$ 144,282				$ 104,428	$ 67,878								$ 1,467,000
Interest															$ 53,371	$ 53,371
Conversion price			$ 0.13				$ 0.13	$ 0.13							$ 0.25	$ 0.25
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Sales of shares																	1,400,000
Value of shares sold																	$ 600,000
Debt conversion price																	$ 0.43
Shares issued for conversion of debt, shares				505,186
Shares issued for conversion of debt, value				$ 68,200
Conversion price				$ 0.135

SCHEDULE OF FAIR MARKET VALUE (

SCHEDULE OF FAIR MARKET VALUE (Details) - Stock Awards Plan [Member] - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued, beginning balance	4,290,709	3,656,709
Fair value per share, beginning balance		$ 0.001
Weighted average market value per share, beginning balance	$ 0	$ 0
Number of shares, shares issued	711,000	552,000
Weighted average market value per share, shares issued	$ 0.20	$ 0.22
Number of shares issued, beginning balance		4,208,709
Weighted average market value per share, ending balance	$ 0.01	$ 0
Number of shares issued, ending balance	5,001,709
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value per share, beginning balance	$ 0.001
Shares issued price fair value per share	0.15	0.16
Fair value per share, ending balance	0.001	0.001
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value per share, beginning balance	0.41
Shares issued price fair value per share	0.48	0.32
Fair value per share, ending balance	$ 0.48	$ 0.32

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of outstanding, granted	233,163
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of outstanding, begining balance	524,000	668,000
Weighted exercise price per share, beginning balance	$ 0.44	$ 0.55
Number of outstanding, granted
Weighted exercise price per share, granted
Number of outstanding, exercised
Weighted exercise price per share, exercised
Number of outstanding, forfeited/cancelled	(144,000)	(96,000)
Weighted exercise price per share, forfeited/cancelled	$ 0.11	$ 0.92
Number of outstanding, ending balance	380,000	572,000
Weighted exercise price per share, ending balance	$ 0.48	$ 0.45
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price per share, beginning balance	0.001	0.001
Exercise Price per share, forfeited/cancelled	0.001	1.09
Exercise Price per share,ending balance	0.001	0.001
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price per share, beginning balance	0.95	1.21
Exercise Price per share, forfeited/cancelled	0.32	1.21
Exercise Price per share,ending balance	$ 0.95	$ 1.21

SCHEDULE OF STOCK OPTION VESTED

SCHEDULE OF STOCK OPTION VESTED (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.95
Options Outstanding Number of options | shares	380,000
Weighted average exercise price per share	$ 0.48
Options outstanding weighted average remaining contractual life years	6 months 25 days
Options outstanding aggregate intrinsic value | $	$ 7,650
Options Exercisable Number of options | shares	380,000
Exercisable Options Weighted average exercise price per share	$ 0.48
Exercisable Options Weighted average remaining contractual life years	6 months 25 days
Exercisable Options Aggregate Intrinsic value | $	$ 7,650
Exercise Price, Lower Range	$ 0.001
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.001
Options Outstanding Number of options | shares	45,000
Weighted average exercise price per share	$ 0.001
Options outstanding weighted average remaining contractual life years	9 months 29 days
Options outstanding aggregate intrinsic value | $	$ 7,650
Options Exercisable Number of options | shares	45,000
Exercisable Options Weighted average exercise price per share	$ 0.001
Exercisable Options Weighted average remaining contractual life years	9 months 29 days
Exercisable Options Aggregate Intrinsic value | $	$ 7,650
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.18
Options Outstanding Number of options | shares	45,000
Weighted average exercise price per share	$ 0.18
Options outstanding weighted average remaining contractual life years	29 days
Options outstanding aggregate intrinsic value | $
Options Exercisable Number of options | shares	45,000
Exercisable Options Weighted average exercise price per share	$ 0.18
Exercisable Options Weighted average remaining contractual life years	29 days
Exercisable Options Aggregate Intrinsic value | $
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.19
Options Outstanding Number of options | shares	45,000
Weighted average exercise price per share	$ 0.19
Options outstanding weighted average remaining contractual life years	6 months 29 days
Options outstanding aggregate intrinsic value | $
Options Exercisable Number of options | shares	45,000
Exercisable Options Weighted average exercise price per share	$ 0.19
Exercisable Options Weighted average remaining contractual life years	6 months 29 days
Exercisable Options Aggregate Intrinsic value | $
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.20
Options Outstanding Number of options | shares	45,000
Weighted average exercise price per share	$ 0.20
Options outstanding weighted average remaining contractual life years	4 months 2 days
Options outstanding aggregate intrinsic value | $
Options Exercisable Number of options | shares	45,000
Exercisable Options Weighted average exercise price per share	$ 0.20
Exercisable Options Weighted average remaining contractual life years	4 months 2 days
Exercisable Options Aggregate Intrinsic value | $
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Upper Range	$ 0.95
Options Outstanding Number of options | shares	200,000
Weighted average exercise price per share	$ 0.95
Options outstanding weighted average remaining contractual life years	6 months 3 days
Options outstanding aggregate intrinsic value | $
Options Exercisable Number of options | shares	200,000
Exercisable Options Weighted average exercise price per share	$ 0.95
Exercisable Options Weighted average remaining contractual life years	6 months 3 days
Exercisable Options Aggregate Intrinsic value | $

STOCK OPTION PLAN AND STOCK-B_3

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)									9 Months Ended
	Aug. 04, 2023	Apr. 19, 2023	Aug. 02, 2022	Apr. 11, 2022	Apr. 02, 2022	Feb. 18, 2022	Jan. 10, 2022	Jan. 19, 2021	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants									233,163
Options exercisable, weighted-average remaining estimated life									5 months 23 days
Options exercisable, intrinsic value									$ 7,650
Stock option exercises									$ 0	$ 0
2021 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock awards stock appreciation rights percentage								15%
Number of shares authorized under plan									5,001,709
Number of common stock, grants									0	0
Share-based payment, expense									$ 157,268	$ 142,630
Share based compensation									711,000	552,000
Number of common stock, forfeited									144,000	96,000
Number of shares available for grant									20,875,870
2021 Plan [Member] | Four Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants			82,000		70,000		40,000
Stock granted during period value share based compensation		$ 50,200	$ 26,240		$ 12,110		$ 6,400
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value		$ 0.46	$ 0.32		$ 0.173		$ 0.16
Share based compensation arrangement by share based payment award options grants in period gross		110,000
2021 Plan [Member] | Two Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants						100,000
Stock granted during period value share based compensation						$ 16,000
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value						$ 0.16
2021 Plan [Member] | Medical Advisory Board Member [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants					10,000
Stock granted during period value share based compensation					$ 1,730
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value					$ 0.173
2021 Plan [Member] | Three Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants				250,000
Stock granted during period value share based compensation				$ 43,250
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value				$ 0.173
2021 Plan [Member] | Scientific Advisory Board [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock, grants	477,000	4,000
Stock granted during period value share based compensation	$ 71,312	$ 1,790
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value	$ 0.15	$ 0.45
2021 Plan [Member] | Three Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock granted during period value share based compensation	$ 17,940
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value	$ 0.15
Share based compensation arrangement by share based payment award options grants in period gross	120,000
2021 Plan [Member] | Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized under plan									90,000

SCHEDULE OF NON CONTROLLING INT

SCHEDULE OF NON CONTROLLING INTEREST (Details) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss attributable to the non-controlling interest	$ (34,777)	$ (764)	$ (32,894)	$ (79,507)	$ (11,691)	$ (51,116)	$ (68,435)	$ (142,314)
Subsidiaries [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss Subsidiary							(289,191)		$ (817,151)
Net loss attributable to the non-controlling interest							68,435		193,372
Net loss affecting Bioxytran							(220,756)		(623,780)
Accumulated losses							(3,861,549)		(3,594,287)
Accumulated losses attributable to the non-controlling interest							820,013		751,578
Accumulated losses Bioxytran							(3,041,536)		(2,842,709)
Net equity non-controlling interest							$ (659,063)		$ (590,628)

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details Narrative) - shares	Sep. 30, 2023	Dec. 31, 2022
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares issued	144,355,355	123,252,235
Common stock, shares outstanding	144,355,355	123,252,235
Pharmalectin, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares issued	19,650,000	19,650,000
Common stock, shares outstanding	19,650,000	19,650,000
Pharmalectin, Inc. [Member] | Parent Company [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares outstanding	15,000,000	15,000,000
Pharmalectin, Inc. [Member] | Affiliate [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, shares outstanding	4,650,000
Options outstanding	4,500,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Sep. 30, 2023 USD ($)
Employment Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of severance upon termination	$ 50,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

9 Months Ended

Oct. 30, 2023

Oct. 27, 2023

Aug. 04, 2023

Apr. 19, 2023

Aug. 02, 2022

Apr. 02, 2022

Jan. 10, 2022

Sep. 30, 2023

Sep. 30, 2022

Sep. 19, 2023

Jul. 26, 2023

May 15, 2023

Apr. 18, 2023

Feb. 10, 2023

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

233,163

Market price

$ 0.135

$ 0.20

$ 0.32

$ 0.32

$ 0.32

2021 Plan [Member]

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

0

0

Market price

$ 0.20

2021 Plan [Member] | Scientific Advisory Board [Member]

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

477,000

4,000

2021 Plan [Member] | Four Board Members [Member]

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

82,000

70,000

40,000

Subsequent Event [Member] | 2021 Plan [Member]

Subsequent Event [Line Items]

Share based compensation forfeited

45,000

Subsequent Event [Member] | 2021 Plan [Member] | Scientific Advisory Board [Member]

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

53,815

Stock granted during period value share based compensation gross

$ 10,386

Market price

$ 0.193

Subsequent Event [Member] | 2021 Plan [Member] | Four Board Members [Member]

Subsequent Event [Line Items]

Gross number of share options (or share units) granted during the period.

233,163

Stock granted during period value share based compensation gross

$ 45,000

Market price

$ 0.193